ABL101 / ABL Bio - LARVOL DELTA

ABL Bio Announces Bispecific Antibody Non-Clinical Results for ’BCMA 4-1BB’ [Google translation] (Hankyung) - "ABL Bio announced on the 29th that it will participate in the 'Antibody Engineering & Therapeutics' conference held in San Diego, USA from the 4th to the 8th of next month (local time). At this conference, the non-clinical results of 'ABL101' will be presented as a poster....The monkey toxicity test has now been completed, and phase 1 clinical trials are being prepared next year....At this conference, ABL Bio will present a poster showing the anticancer efficacy of ABL101 confirmed in a mouse model and the inhibitory effect of cancer cell growth through immune memory response. This poster will also include data on T-cell activation and tumor killing effects confirmed by the combined administration of ABL101 and T-cell engager bispecific antibody (BCMA/CD3)."

New P1 trial • Preclinical • Oncology